Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

41. Mepolizumab (Nucala) - as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older

Mepolizumab (Nucala) - as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older Published 08 April 2019 1 Product update SMC2139 mepolizumab 100mg powder for solution for injection (Nucala®) GlaxoSmithKline UK Limited 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission mepolizumab (Nucala®) is accepted for restricted use within NHSScotland. Indication under review: as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older. SMC restriction: patients who have eosinophils of at least 150 cells per microlitre (0.15 x 10 9 /L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance

2019 Scottish Medicines Consortium

42. Benralizumab (asthma) - Addendum to Commission A18-11

Benralizumab (asthma) - Addendum to Commission A18-11 1 Translation of addendum A18-42 Benralizumab (Asthma) – Addendum zum Auftrag A18-11 (Version 1.0; Status: 13 July 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 13 July 2018 1.0 Commission: A18-42 Version: Status: IQWiG Reports – Commission No. A18-42 Benralizumab (asthma) – Addendum (...) to Commission A18-11 1 Addendum A18-42 Version 1.0 Benralizumab – Addendum to Commission A18-11 13 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Benralizumab (asthma) – Addendum to Commission A18-11 Commissioning agency: Federal Joint Committee Commission awarded on: 26 June 2018 Internal Commission No.: A18-42 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

43. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Full Text available with Trip Pro

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both clinically efficacious and safe. However, in line with the current regulatory guidance from the European Medicines Agency, allergen immunotherapy (AIT) products must demonstrate their efficacy and safety in pivotal phase III trials for registration.We sought to investigate (...) the efficacy and safety of sublingual high-dose liquid birch pollen extract (40,000 allergy units native [AUN]/mL) in adults with birch pollen allergy.A randomized, double-blind, placebo-controlled, parallel-group multicenter trial was conducted in 406 adult patients with moderate-to-severe birch pollen-induced allergic rhinoconjunctivitis with or without mild-to-moderate controlled asthma. Treatment was started 3 to 6 months before the birch pollen season and continued during the season in 40 clinical

2019 EvidenceUpdates

44. High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. Full Text available with Trip Pro

High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. 30860552 2019 03 25 2019 09 12 1538-3598 321 10 2019 03 12 JAMA JAMA High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. 1003-1005 10.1001/jama.2019.0052 Brustad Nicklas N Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Eliasen Anders U AU Copenhagen Prospective Studies on Asthma (...) in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Stokholm Jakob J Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Bønnelykke Klaus K Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Bisgaard Hans H Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Chawes Bo L BL Copenhagen

2019 JAMA Controlled trial quality: uncertain

45. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate (Abstract)

Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate The safety of long-acting β-agonists added to inhaled corticosteroids for the treatment of persistent asthma has been controversial.We sought to determine whether administering formoterol in combination with mometasone furoate increases the risk of serious asthma outcomes (SAOs) compared with mometasone furoate alone. This clinical trial is registered as NCT01471340.We conducted a 26-week, randomized (...) , double-blind trial in adolescent and adult patients (≥12 years) with persistent asthma in 35 countries with the primary objective of evaluating whether mometasone furoate-formoterol increases the risk of SAOs (adjudicated hospitalization, intubation, or death) compared with mometasone furoate alone. The key efficacy end point was asthma exacerbation (composite of hospitalization of ≥24 hours, emergency department visits of <24 hours requiring systemic corticosteroids, or use of systemic

2019 EvidenceUpdates

46. Benralizumab for treating severe eosinophilic asthma

Benralizumab for treating severe eosinophilic asthma Benr Benralizumab for treating se alizumab for treating sev vere ere eosinophilic asthma eosinophilic asthma T echnology appraisal guidance Published: 6 March 2019 www.nice.org.uk/guidance/ta565 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights). Last updated September 2019Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Benralizumab for treating severe eosinophilic asthma (TA565) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated September 2019 Page 2 of 23Contents Contents 1 Recommendations 4 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

47. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma Full Text available with Trip Pro

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg (...) or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS dose of ≤5 mg, those with a ≥50% reduction in prescribed maintenance OCS dose and asthma exacerbation rate. Safety was also assessed.At week 40, the percentage reduction from baseline in the final daily average OCS dose

2019 EvidenceUpdates

48. Less puffing, more breathing? Intermittent inhaled steroids for asthma

with intermittent treatment. 1,2 • Previous systematic review 3 (6 RCTs; 1211 children and adults) of intermittent versus daily ICS (excluded ICS/LABA combination trials) found: o No difference in risk of exacerbation. o Fewer asthma-controlled days with intermittent versus daily ICS. o For children: daily ICS resulted in ~0.5cm less growth (height) at ~1 year. 3 Context: • Up to 75% of asthmatics have mild asthma. 4 • Guidelines recommend daily ICS for mild persistent asthma, 5 but only ~50% adhere. 6 (...) Less puffing, more breathing? Intermittent inhaled steroids for asthma March 4, 2019 (en français) Less puffing, more breathing? Intermittent inhaled steroids for asthma Clinical Question: In patients with mild persistent asthma, is intermittent use of inhaled corticosteroids (ICS) as effective as daily use? Bottom Line: In patients with mild persistent asthma, intermittent use of ICS or ICS/LABA is similar to daily ICS in preventing exacerbations but is associated with ~5 fewer weeks per year

2019 Tools for Practice

49. Acceptance and Commitment Therapy for Parental Management of Childhood Asthma: An RCT Full Text available with Trip Pro

Acceptance and Commitment Therapy for Parental Management of Childhood Asthma: An RCT Few trials have been conducted to address the psychological difficulties of parents in managing their child's asthma. Fostering parental psychological flexibility through Acceptance and Commitment Therapy (ACT) may help parents to accept these psychological difficulties and improve their management of childhood asthma.In this randomized controlled trial, a 4-session, group-based ACT plus asthma education (ACT (...) group) was compared with an asthma education talk plus 3 telephone follow-ups (control group) to train parents of children diagnosed with asthma. The use of health care services due to asthma exacerbations in children and the psychological well-being of their parents were assessed before, immediately after, and at 6 months after the intervention.A total of 168 parents and their children aged 3 to 12 years with asthma were consecutively recruited in a public hospital in Hong Kong. When compared

2019 EvidenceUpdates

50. The long-term effect of an exercise and diet intervention in asthma patients: a 1-year follow-up on a randomised controlled trial. Full Text available with Trip Pro

The long-term effect of an exercise and diet intervention in asthma patients: a 1-year follow-up on a randomised controlled trial. In the EFFORT (Effects of Exercise and Diet in Nonobese Asthma Patients - A Randomized Controlled Trial) study, maximum exercise capacity (V'O2max) increased significantly within a 2-month high-intensity spinning period. Furthermore, the study concluded that only the combined exercise and diet intervention improved asthma control, significantly. This study examined (...) whether original improvements in V'O2max and asthma control were present 1 year after intervention completion.In the original trial, 149 patients were randomised into four study groups. Participants were assessed with an incremental cycle ergometer test and the Asthma Control Questionnaire (ACQ). Of the 149 patients, 66 accepted the follow-up invitation. Participants were distributed in their original groups: exercise group (n=18), diet group (n=117), combined diet and exercise group (n=115

2019 ERJ open research Controlled trial quality: uncertain

51. The Reliability of Adjusting Stepped Care Based on FeNO Monitoring for Patients with Chronic Persistent Asthma. Full Text available with Trip Pro

The Reliability of Adjusting Stepped Care Based on FeNO Monitoring for Patients with Chronic Persistent Asthma. To examine the feasibility of fractional exhaled nitrous oxide (FeNO) guided stepped care in patients with chronic persistent asthma.160 patients with asthma were enrolled and randomly divided into study and control groups, and were given standardized treatment according to GINA 2014. All patients were evaluated every 3 months and their medication was adjusted according to the results (...) of asthma.

2019 Open medicine (Warsaw, Poland) Controlled trial quality: uncertain

52. The effectiveness of relaxation training in the quality of life and anxiety of patients with asthma. Full Text available with Trip Pro

The effectiveness of relaxation training in the quality of life and anxiety of patients with asthma. With a 5-10% global prevalence, asthma, as a chronic condition which can strongly affect the quality of life of patients and care givers, needs comprehensive approach, including medications and psychological techniques, to get the optimal control. This is why the current study aimed to assess the effectiveness of the Papworth method relaxation training among patients with asthma, considering (...) reduced anxiety and improved quality of life.Through a randomized controlled trial, 30 patients with asthma 20-45 years of age referring to a tertiary university hospital in Tehran enrolled two study groups, including disease cases and controls. The Papworth method of relaxation was used and was finally assessed for its effectiveness by two questionnaires, namely STAI for anxiety and SF-36 for the quality of life. Pre-test and post-test were done for both groups.The scores of the anxiety questionnaire

2019 Advances in respiratory medicine Controlled trial quality: uncertain

53. Tiotropium (Spiriva Respimat) - as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year

Tiotropium (Spiriva Respimat) - as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year Published 14 January 2019 www.scottishmedicines.org.uk Product update SMC2118 tiotropium 2.5 microgram solution for inhalation (Spiriva® Respimat®) Boehringer Ingelheim Limited 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product (...) and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission tiotropium (Spiriva® Respimat®) is accepted for use within NHSScotland. Indication under review: as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. Tiotropium has previously been accepted for use

2019 Scottish Medicines Consortium

54. Bronchial thermoplasty for severe asthma

Bronchial thermoplasty for severe asthma Bronchial thermoplasty for se Bronchial thermoplasty for sev vere asthma ere asthma Interventional procedures guidance Published: 19 December 2018 nice.org.uk/guidance/ipg635 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However (...) should be interpreted in a way that would be inconsistent with compliance with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. This guidance replaces IPG419. 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of bronchial thermoplasty for severe asthma is adequate to support

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

55. Association of age at first severe RSV disease with subsequent risk of severe asthma: a population-based cohort study Full Text available with Trip Pro

Association of age at first severe RSV disease with subsequent risk of severe asthma: a population-based cohort study In a population-based cohort study, we determined the association between the age at first severe respiratory syncytial virus (RSV) disease and subsequent asthma.Incidence rates and rate ratios of the first asthma-associated hospitalization after 2 years of age in children hospitalized for RSV disease at <3 months, 3 to <6 months, 6 to <12 months, and 12-24 months of age were (...) calculated.The incidence of asthma-associated hospitalization per 1000 child-years among children hospitalized for RSV disease at <3 months of age was 0.5 (95% confidence interval [CI], .2-.7); at 3 to <6 months of age, 0.9 (95% CI,.5-1.3); at 6 to <12 months of age, 2.0 (95% CI, 1.4-2.7); and at 12-24 months of age, 1.7 (95% CI, 1.0-2.5). The rate ratio of hospitalization for asthma was 2-7-fold greater among children hospitalized for RSV disease at ages ≥6 months than that among those hospitalized for RSV

2019 EvidenceUpdates

56. Randomized Clinical Trial Comparing Breath-Enhanced to Conventional Nebulizers in the Treatment of Children with Acute Asthma (Abstract)

Randomized Clinical Trial Comparing Breath-Enhanced to Conventional Nebulizers in the Treatment of Children with Acute Asthma To compare the efficacy of a breath-enhanced and a conventional jet nebulizer in the treatment of children with moderate to severe acute asthma.We enrolled subjects between 6 and 18 years of age presenting to the emergency department (ED) with acute asthma and an initial forced expiratory volume in 1 second (FEV1) <70% of predicted. We excluded patients with chronic (...) disease, who required immediate resuscitation, or failed spirometry. Subjects were randomized to breath-enhanced or conventional jet delivery of a 5-mg albuterol treatment. Our primary outcome was change in FEV1, and secondary outcomes included change in clinical asthma scores, ED length of stay, disposition, and side effects. Student t test and multivariable linear regression were used to evaluate the primary outcome.In total, 497 patients were assessed for eligibility with 118 enrolled and 107

2019 EvidenceUpdates

57. Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V

Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab (Asthma) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. 19-74 Dupilumab (asthma) – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-74 Version 1.0 Dupilumab (asthma) 28 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dupilumab (asthma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 August 2019 Internal Commission No.: A19-74 Address of publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

58. Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V

Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Mepolizumab (Asthma bei Jugendlichen und Kindern ab 6 Jahren) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 20 December 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A18-58 Mepolizumab (asthma in adolescents and children aged 6 years and older) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-58 Version 1.0 Mepolizumab (asthma in adolescents and children aged 6 years and older) 20 December 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Mepolizumab (asthma

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

59. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature (Abstract)

treatment we present studies showing a dose-response relationship in asthmatic patients treated with OCS and then consider by organ systems the undesired effects demonstrated in clinical and epidemiological studies in patients with OCS-dependent asthma. It was found that the risk of developing various OCS-related complications, including infections, diabetes and osteoporosis as well as psychiatric disorders, was higher for patients with long-term exposure to OCS compared with control groups. In addition (...) Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature This review provides an overview of the role of long-term treatment of severe asthma with oral corticosteroids (OCS) and its associated side-effects in adults. It is based on a systematic literature search conducted in MEDLINE, Embase and the Cochrane Library to identify relevant studies. After a short overview of severe asthma and its

2018 EvidenceUpdates

60. Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma

that the lack of evidence available for other treatment options meant it was unfeasible to make a robust comparison with tiotropium of the clinical and cost-effectiveness of the other treatment options. ? Welsh clinical experts contacted by the All Wales Therapeutics and Toxicology Centre (AWTTC) commented that there are very limited effective treatment options at the later stages of asthma treatment, and that tiotropium is currently used as a treatment option for asthmatics at the add-on therapy stage (...) Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma Tiotropium (Spiriva ® Respimat ® ). Reference number 1882. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Tiotropium (Spiriva ® Respimat ® ) 2.5 microgram, inhalation solution Company: Boehringer Ingelheim Ltd Licensed indication under consideration: add-on maintenance bronchodilator treatment in patients aged 6 years to < 18 years with severe

2018 All Wales Medicines Strategy Group